Suppr超能文献

用于丙型肝炎病毒(HCV)RNA定量的带内部阳性对照的TaqMan扩增系统。

TaqMan amplification system with an internal positive control for HCV RNA quantitation.

作者信息

Castelain Sandrine, Descamps Véronique, Thibault Vincent, François Catherine, Bonte Dorine, Morel Virginie, Izopet Jacques, Capron Dominique, Zawadzki Patricia, Duverlie Gilles

机构信息

Laboratoire de Virologie, CHU-Hôpital sud, Faculté de Médecine, 80036 Amiens Cedex, France.

出版信息

J Clin Virol. 2004 Nov;31(3):227-34. doi: 10.1016/j.jcv.2004.03.009.

Abstract

BACKGROUND

Quantitation of hepatitis C virus (HCV) RNA has become an essential tool for monitoring antiviral therapies in chronically infected patients. Different quantitative HCV RNA assays have been reported, mainly using techniques based on signal amplification with branched DNA (bDNA) technology or target sequence amplification by reverse-transcription PCR method (RT-PCR).

OBJECTIVES AND STUDY DESIGN

An RT-PCR assay using TaqMan (fluorescence-based real-time PCR) and minor groove binding (MGB) probes was designed for the quantitative determination of HCV RNA in the clinical samples. Calculation of the concentration of HCV RNA was based on an external standard curve in the presence of an internal positive control (IPC).

RESULTS

The assay detected 550 international units (IU)/mL with >95% probability of a positive result, with a linear range extending up to 10,000,000 IU/mL. The test exhibited good reproducibility with intra-assay and inter-assay coefficients of variation (CV) of 1.6% and 3.2%, respectively. All the major HCV genotypes were quantified with equivalent efficiency and accuracy. HCV genotypes 5 and 6 have also been amplified but too few samples have been tested. The performance of this new assay for quantitation of HCV viremia was evaluated with 213 anti-HCV positive sera, 120 of which corresponded to 30 patients sampled during the therapy. We used the Amplicor HCV Monitor assay (Roche Diagnostics, France) and the bDNA VERSANT HCV RNA assay (Bayer Diagnostics, France) to analyze 173 and 40 samples, respectively. The assay described here was significantly correlated with both commercial assays (R2 = 0.9535, P < 0.0001 and R2 = 0.8508, P < 0.0001, respectively).

CONCLUSION

The present study illustrated the high reproducibility and reliability of our TaqMan HCV assay. Moreover, the monitoring of viral decline with our assay gave the same results as those obtained with the commercial assays indicating that this new technique provides an attractive approach for measuring HCV viral load.

摘要

背景

丙型肝炎病毒(HCV)RNA定量已成为监测慢性感染患者抗病毒治疗的重要工具。已报道了不同的HCV RNA定量检测方法,主要采用基于分支DNA(bDNA)技术的信号放大或逆转录PCR方法(RT-PCR)进行靶序列扩增。

目的和研究设计

设计了一种使用TaqMan(基于荧光的实时PCR)和小沟结合(MGB)探针的RT-PCR检测方法,用于临床样本中HCV RNA的定量测定。HCV RNA浓度的计算基于存在内部阳性对照(IPC)时的外标曲线。

结果

该检测方法以>95%的阳性结果概率检测到550国际单位(IU)/mL,线性范围扩展至10,000,000 IU/mL。该检测方法具有良好的重复性,批内和批间变异系数(CV)分别为1.6%和3.2%。所有主要HCV基因型的定量效率和准确性相当。HCV基因型5和6也已被扩增,但检测的样本太少。使用213份抗HCV阳性血清评估了这种新的HCV病毒血症定量检测方法的性能,其中120份对应于治疗期间采样的30名患者。我们分别使用Amplicor HCV Monitor检测方法(法国罗氏诊断公司)和bDNA VERSANT HCV RNA检测方法(法国拜耳诊断公司)分析了173份和40份样本。这里描述的检测方法与两种商业检测方法均显著相关(R2分别为0.9535,P < 0.0001和R2为0.8508,P < 0.0001)。

结论

本研究说明了我们的TaqMan HCV检测方法具有高重复性和可靠性。此外,用我们的检测方法监测病毒载量下降与商业检测方法得到的结果相同,表明这种新技术为测量HCV病毒载量提供了一种有吸引力的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验